Gan & Lee Pharmaceuticals. (SHA:603087)
China · Delayed Price · Currency is CNY 68.73
+0.83 (1.22%)
Jul 31, 2026, 3:00 PM CST
SHA:603087 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 3,945 | 4,052 | 3,045 | 2,608 | 1,712 | 3,612 |
Revenue Growth | 13.70% | 33.06% | 16.77% | 52.31% | -52.60% | 7.44% |
Gross Profit Gross Profit Growth | 2,965 | 3,067 | 2,268 | 1,883 | 1,268 | 3,212 |
Operating Income Operating Income Growth | 728.48 | 759.74 | 294.58 | 180.03 | -675.68 | 1,390 |
Net Income Net Income Growth | 1,024 | 1,144 | 614.66 | 340.07 | -439.52 | 1,453 |
Earnings Per Share EPS Growth | 1.73 | 1.93 | 1.04 | 0.60 | -0.78 | 2.59 |
EPS Growth | 22.66% | 85.58% | 73.33% | - | - | 12.12% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
China China Growth | 3,513 |
International International Growth | 538.69 |
Total Total Growth | 4,052 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 3,416 | 3,489 | 2,403 | 4,853 | 4,728 | 5,206 |
Total Debt Total Debt Growth | 2.27 | 3.74 | 4.64 | 7.62 | 14.01 | 17.24 |
Net Cash (Debt) Net Cash Growth | 3,414 | 3,486 | 2,399 | 4,846 | 4,714 | 5,189 |
Net Cash Growth | 45.05% | 45.32% | -50.50% | 2.80% | -9.16% | 13.86% |
Net Cash Per Share Net Cash Per Share Growth | 5.77 | 5.88 | 4.06 | 8.55 | 8.37 | 9.25 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 797.2 | 784.28 | 537.31 | 109.45 | 296.68 | 1,078 |
Capital Expenditures CapEx Growth | -1,077 | -926.09 | -440.8 | -553.06 | -983.44 | -692.08 |
Free Cash Flow Free Cash Flow Growth | -280.13 | -141.81 | 96.51 | -443.61 | -686.76 | 386.09 |
Free Cash Flow Growth | - | - | - | - | - | -41.43% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 75.16% | 75.68% | 74.48% | 72.21% | 74.07% | 88.93% |
Operating Margin | 18.46% | 18.75% | 9.67% | 6.90% | -39.46% | 38.49% |
Pretax Margin | 27.43% | 30.35% | 20.70% | 11.74% | -34.02% | 46.95% |
Profit Margin | 25.96% | 28.22% | 20.18% | 13.04% | -25.67% | 40.22% |
FCF Margin | -7.10% | -3.50% | 3.17% | -17.01% | -40.11% | 10.69% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 1.000 | 1.000 | 1.500 | 0.200 | - | 0.300 |
Dividend Per Share Growth | -33.33% | -33.33% | 650.00% | - | - | -25.00% |
Dividend Yield | 1.45% | 1.50% | 3.53% | 0.40% | - | 0.45% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 39.68 | 35.43 | 42.84 | 91.35 | - | 27.19 |
Forward PE | 26.64 | 33.53 | 28.27 | 52.09 | 11.40 | 25.81 |
P/FCF Ratio | - | - | 272.84 | - | - | 102.30 |
PS Ratio | 10.37 | 10.00 | 8.65 | 11.91 | 10.76 | 10.94 |